Table 1.
Time-action of rapid-acting insulin analogs versus human regular insulin.
| Insulin Type | Brand name | Onset of Action (min) | Peak Action (hr) | Duration of Action (hr) |
|---|---|---|---|---|
| Short-acting | ||||
| Human regular insulin | Humulin® R Novolin® R Insuman® R | 30–60 | 2–4 | 5–8 |
| Rapid-acting | ||||
| Insulin lispro | Humalog®, Admelog | 15–30 | 0.5–2.5 | ≤5 |
| Insulin aspart | Novolog® (26) | 15 | 1–3 | 3–5 |
| Insulin glulisine | Apidra® | 12–30 | 1.5 | ~5.3 |
| Faster rapid-acting | ||||
| Faster insulin aspart | Fiasp® (30) | ~16–20 | ~1.5–2.2 | ~5–7 |
| Inhaled human insulin | Afrezza® (34) | ~12 | 0.5–0.9 | 1.5–3 |
Time-action parameters taken from Beals et al (28) and IBM Micromedex® Pharmaceutical Knowledge database, unless otherwise indicated.